Why do the largest biopharma companies struggle to deliver above-average shareholder returns? The short answer: complex, wide-ranging portfolios that undermine focus. According to Bain research, the biggest value creators in biopharma are category leaders. But even category leaders can spread their resources too thin. Companies that combine category leadership with portfolio focus create a powerful multiplier effect and significantly outperform their competitors.